Lidocaine for opioid sparing in vaso-occlusive crisis of sickle cell disease

Phase 3, randomised trial in sickle cell disease (SCD) comparing Lidocaine + standard of care with Standard of care alone (2 arms). Primary endpoint: Cumulative parenteral opioid dose. Planned start Jul 2026; status: authorised.